LY3039478
- Product Name
- LY3039478
- CAS No.
- 1421438-81-4
- Chemical Name
- LY3039478
- Synonyms
- LY3039478;Crenigacestat;LY3039478(Crenigacestat);CRENIGACESTAT (LY3039478);LY3039478; LY 3039478; LY-3039478; CRENIGACESTAT;4-trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6;Inhibitor,γ-secretase,Crenigacestat,liver,LY 3039478,Notch,Gamma secretase,inhibit,LY-3039478,CCRCC;4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide;N-[(1S)-2-[[(7S)-6,7-Dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluorobutanamide;Butanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-
- CBNumber
- CB52677403
- Molecular Formula
- C22H23F3N4O4
- Formula Weight
- 464.44
- MOL File
- 1421438-81-4.mol
LY3039478 Property
- Boiling point:
- 818.7±65.0 °C(Predicted)
- Density
- 1.41±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- ≥23.2 mg/mL in DMSO; insoluble in H2O; ≥89.4 mg/mL in EtOH with ultrasonic
- form
- solid
- pka
- 12.75±0.20(Predicted)
N-Bromosuccinimide Price
- Product number
- 27919
- Product name
- Crenigacestat
- Packaging
- 1mg
- Price
- $44
- Updated
- 2024/03/01
- Product number
- 27919
- Product name
- Crenigacestat
- Packaging
- 10mg
- Price
- $384
- Updated
- 2024/03/01
- Product number
- 27919
- Product name
- Crenigacestat
- Packaging
- 5mg
- Price
- $202
- Updated
- 2024/03/01
- Product number
- L468970
- Product name
- LY3039478
- Packaging
- 1mg
- Price
- $160
- Updated
- 2021/12/16
- Product number
- CS-5807
- Product name
- Crenigacestat
- Purity
- 98.62%
- Packaging
- 5mg
- Price
- $168
- Updated
- 2021/12/16
LY3039478 Chemical Properties,Usage,Production
Uses
LY 3039478 is used in the preparation of medicaments for combination antitumor therapy with Notch and PD-1 or PD-Li inhibitors.
Biological Activity
ly3039478 is a novel and potent notch inhibitor with ic50 of 0.41 nm.the novel and unique notch inhibitor, ly3039478, has progressed into clinical development by lilly co. ltd. ly3039478 displays the best overall profile and is unique within the sar investigated. ly3039478 displays interesting atropisomer phenomena. the average ly3039478 major/minor rotational isomer ratio ranged between 14 and 28 in plasma. the crystalline monohydrate form of ly3039478 consists of a single rotational isomer and is chemically and physically stable for at least 14 days under accelerated stability test conditions.
References
warren j. porter. discovery of a novel notch inhibitor. the 8th sci-rsc symposium on proteinase inhibitor design april 15-16, 2013, basel, switzerland.